Provided by Tiger Trade Technology Pte. Ltd.

MoonLake Immunotherapeutics

17.32
-0.4300-2.42%
Post-market: 17.20-0.1200-0.69%19:58 EDT
Volume:478.92K
Turnover:8.34M
Market Cap:1.24B
PE:-4.91
High:17.89
Open:17.68
Low:17.19
Close:17.75
52wk High:62.75
52wk Low:5.95
Shares:71.37M
Float Shares:40.42M
Volume Ratio:0.59
T/O Rate:1.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5300
EPS(LYR):-3.5300
ROE:-60.78%
ROA:-33.92%
PB:4.06
PE(LYR):-4.91

Loading ...

MoonLake Immunotherapeutics management to meet with BTIG

TIPRANKS
·
Mar 27

MoonLake Immunotherapeutics Shares Rise After Wolfe Research Upgrade

MT Newswires Live
·
Mar 24

MoonLake Immunotherap Raised to Outperform From Underperform by Wolfe Research

Dow Jones
·
Mar 23

MoonLake upgraded to Outperform from Underperform at Wolfe Research

TIPRANKS
·
Mar 23

Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Solid Biosciences (SLDB) and Merck & Company (MRK)

TIPRANKS
·
Mar 20

Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Cormorant’s Large Share Purchase

Simply Wall St.
·
Mar 20

MoonLake Immunotherap Raised to Buy From Neutral by Rothschild & Co

Dow Jones
·
Mar 20

MoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn

TIPRANKS
·
Mar 19

MoonLake Immunotherapeutics: Sonelokimab’s Differentiated IL‑17A/F Profile and Multibillion-Dollar Potential Underpin Buy Rating Despite HS Trial Concerns

TIPRANKS
·
Mar 13

MoonLake Immunotherap Is Maintained at Buy by Clear Street

Dow Jones
·
Mar 11

Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Sarepta Therapeutics (SRPT) and vTv Therapeutics (VTVT)

TIPRANKS
·
Mar 11

MoonLake price target raised to $70 from $45 at Clear Street

TIPRANKS
·
Mar 11

MoonLake Immunotherapeutics (MLTX) Is Down 6.3% After Wider 2025 Loss And SLK BLA Timeline Update – Has The Bull Case Changed?

Simply Wall St.
·
Mar 03

MoonLake Immunotherap Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 02

RBC Raises Price Target on MoonLake Immunotherapeutics to $13 From $12, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
Mar 02

RBC Capital Keeps Their Hold Rating on MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Mar 02

MoonLake Immunotherapeutics price target raised to $40 from $32 at H.C. Wainwright

TIPRANKS
·
Mar 02

MoonLake Immunotherapeutics : H.c. Wainwright Raises Target Price to $40 From $32

THOMSON REUTERS
·
Mar 02

Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Genfit (OtherGNFTF)

TIPRANKS
·
Mar 02

MoonLake Immunotherapeutics price target raised to $11 from $10 at Goldman Sachs

TIPRANKS
·
Feb 26